Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Gilead Said PrEP To Prevent HIV Was 'Not A Commercial Opportunity.' Now It's Running Ads For It

    The commercial, aptly titled "I'm on the Pill," is part of a marketing push that has helped turned the use of Truvada for preventing HIV into a $1.3 billion blockbuster, almost 5% of Gilead's annual sales.

    07 August 2018 | Forbes Magazine
  • Mylan, lambasted for EpiPen price hikes, complains of overpriced anti-HIV drugs in the United States

    Mylan, a giant generic drugmaker headquartered in Canonsburg, Pennsylvania, that took a bashing in 2016 for steeply raising the price of its EpiPen that treats severe allergic reactions, has now flipped the tables and is arguing that the United States is wasting billions of dollars on name brand anti-HIV drugs instead of its cheaper alternatives.

    07 August 2018 | Science
  • HIV drug may be more affordable after European court ruling

    THE EUROPEAN COURT of Justice has delivered a ruling that could lead to wider access to affordable PrEP and significant savings on HIV treatment for the HSE. Pharma giant Gilead was today unsuccessful in a case relating to its HIV drug Truvada.

    26 July 2018 | The Journal
  • Court of Justice of the European Union clarifies ‘basic patent’ meaning in SPC dispute

    The dispute involves a summary of product characteristics (SPC) for Gilead-marketed Truvada (emtricitabine/tenofovir disoproxil), an anti-retroviral medication used to treat HIV. Teva, Accord Healthcare, Lupin and Mylan challenged the SPC’s validity, disputing that it is protected by European patent (UK) number 0,915,894.

    26 July 2018 | Life Sciences Intellectual Property Review
  • The 2018 Pipeline Report

    Welcome to the 2018 Pipeline Report, Treatment Action Group’s annual review of therapeutics, diagnostics, vaccines, and preventive technologies in development for HIV, hepatitis C virus (HCV), and tuberculosis, along with immune-based and gene therapies and research toward a cure for HIV.

    24 July 2018 | TAG
  • Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

    GILD’s $14 billion annual income stream could be in jeopardy, because they are literally one drug approval away from an armageddon they admit in their 10-K is coming. A small competitor, CytoDyn Inc. has been struggling for over a decade to get PRO 140 approved as a salvage therapy to drug resistant HIV patients. After two successful phase 3 studies (pivotal combination therapy and investigational monotherapy), they are in a position to file a BLA for combination therapy, but the real threat is that the data is so robust that it reduces the viral load to undetectable levels and keeps it there without the help of HAART, the current standard of care.

    18 July 2018 | Seeking Alpha
  • How Big Pharma Was Captured by the One Percent

    Generations of lawmakers from both parties bear responsibility for allowing the drug economy to become a racket controlled by hedge funds and the Martin Shkrelis of the smaller firms. The current crisis in drug prices and access—as well as a quieter but no less serious crisis in drug innovation—is the result of decades of regulatory dereliction and corporate capture. History shows there is nothing inevitable or natural about these crises.

    02 July 2018 | New Republic
  • Finns buying HIV prevention drugs from Germany because they're cheaper

    Some Finnish users of PrEP, an HIV prevention drug, get the antiretroviral from Germany because it's not subsidised - and thus much more expensive - in Finland.

    30 June 2018 | YLE
  • “I’m on the Pill” PrEP Ads Begin Airing on National TV

    Gilead Sciences, the maker of Truvada as PrEP, launched the campaign to raise awareness of the HIV prevention method.

    29 June 2018 | Poz
  • European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

    Today’s decision makes BIC/FTC/TAF Gilead’s third FTC/TAF-based STR approved in the European Union in the past three years.

    25 June 2018 | Gilead press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.